

# Health for Humanity 2020 Goals Progress Scorecard

The following Scorecard provides an update on progress we have made against our 2020 Goals.

- + **Exceeded**
- ✓ **Achieved**
- ✓ **On track:** expected to meet the Goal by 2020
- 🕒 **In progress:** so far progressing more slowly than expected; plans are in place to meet the Goal by 2020
- **Off track:** not progressing as expected; currently at risk of not meeting the Goal by 2020

GOAL	2020 TARGET	PROGRESS MADE IN 2016-2019‡	NOTABLE	STATUS
1. Develop and deliver innovative, life-changing solutions to address the world's major health challenges.	Expand the database, documenting the effectiveness, efficacy and safety profile of SIRTURO (bedaquiline) through collaborative efforts to further increase access.	Data from the expanded patient database allowed for publication on effectiveness, efficacy and safety of SIRTURO in two peer-reviewed journals in 2018.	We achieved this target in 2018.	<span style="color: green;">✓</span> <b>Achieved</b>
	Collaborate on Phase 3 trials and make regulatory submissions for rilpivirine long-acting (LA), the first all-injectable depot regimen for HIV.	Regulatory submissions were made: <ul style="list-style-type: none"> <li>• One submission to the U.S. Food and Drug Administration (FDA) by ViiV Healthcare for ViiV's cabotegravir LA together with Janssen's rilpivirine LA.</li> <li>• Two parallel submissions to the European Medicines Agency—one for rilpivirine LA by Janssen and one for cabotegravir LA by ViiV Healthcare.</li> </ul>		<span style="color: green;">✓</span> <b>Achieved</b>
2. Deliver innovative healthcare access and training programs that impact a billion lives in underserved areas.*	Produce and donate 1 billion doses of VERMOX (mebendazole) to treat >100 million children per year at risk for intestinal worms.	0.8 billion doses of VERMOX donated in 42 countries with 415 million children having been targeted for treatment.	Cumulatively 1.6 billion doses of VERMOX donated since 2006.	<span style="color: green;">✓</span> <b>On track</b>

\* "Underserved" refers to populations that are disadvantaged because of ability to pay, ability to access care, ability to access comprehensive healthcare, or other disparities for reasons of race, religion, language group or social status.

‡ Progress against our Health for Humanity 2020 Goals, and associated data have been assured by ERM CVS. See [independent assurance statements by ERM CVS](#).

GOAL	2020 TARGET	PROGRESS MADE IN 2016-2019†	NOTABLE	STATUS
Better Health for All	Deliver HIV/AIDS therapy access to a cumulative 130,000 adults and 5,000 children.	104,000 adult patients and over 700 pediatric patients received access to HIV/AIDS therapy with the branded and generic versions of PREZISTA (darunavir), INTELENCE (etravirine) and EDURANT (rilpivirine).*	<ul style="list-style-type: none"> <li>The estimates of the number of patients receiving access are based on the best available therapy access models developed by our Global Public Health team leveraging published epidemiologic and population data.</li> <li>Healthcare systems in resource-limited settings face considerable challenges in identifying and treating HIV in pediatric and adolescent patients, including lack of laboratory testing and limited technical capacity for switching patients to suitable antiretroviral regimens. Several activities we planned for 2020 will help address these challenges and potentially increase the number of pediatric and adolescent patients we will reach.</li> </ul>	In progress
	Deliver access to MDR-TB therapy to a cumulative 200,000 patients, potentially curing** 157,000 people*** with MDR-TB of the disease.	182,000 patients received access to MDR-TB therapy with SIRTURO (bedaquiline). For 37,000 patients provided access in 2016 and 2017, an estimated 32,000 patients*** have been potentially cured based on the 87.8% cure rate.**	More patients can now benefit from SIRTURO: in 2019, the World Health Organization recommended the use of bedaquiline-containing treatment regimens for all pulmonary drug-resistant TB patients, and we received FDA approval to extend the indication for SIRTURO as part of combination therapy for eligible MDR-TB patients to include adolescents 12 to 18 years of age in the United States.	On track
	Together with partners, train 30,000 skilled birth attendants to assist 6 million births.	Together with partners, trained 74,000 birth attendants, who assisted in 6 million births.		Exceeded
	Support the delivery of 6 million eye care screenings to underserved children and corrective treatments (spectacles) as needed to 100,000 underserved children.	In partnership with Lions Club International, supported delivery of 12 million eye care screenings and corrective treatments (spectacles) to 120,000 underserved children.	Progress in 2019 is estimated based on delivery of eye screenings and corrective treatments (spectacles) in 2018. Actual 2019 data is available after our report data collection cut-off date.	Achieved

\* We revised our calculation methodology to increase accuracy and now report on a 12-month rolling average, which includes a 1.25% wastage and a 75% adherence factor.

\*\* The cure rate is 87.8% for patients treated with bedaquiline-containing regimens, based on *The Lancet Respiratory Medicine*, Volume 392, September 2018, Pages 821-834.

\*\*\* As communicated through the product label, SIRTURO is taken for six months as part of a combination therapy with multiple other drugs; in total, a patient often requires up to two years of treatment to be cured.

† Progress against our Health for Humanity 2020 Goals, and associated data have been assured by ERM CVS. See [independent assurance statements by ERM CVS](#).

GOAL	2020 TARGET	PROGRESS MADE IN 2016-2019‡	NOTABLE	STATUS
3. Collaborate with government, nonprofit and private sector to foster new models of health that improve economic wellbeing and healthcare in key emerging markets.	Activate signature partnerships/ initiatives for five of our largest Consumer Health brands to promote the health and wellbeing of people in need around the world.	BAND-AID® Brand Adhesive Bandages activated the partnership with (RED) to help fund a diverse range of lifesaving HIV/AIDS programs across eight countries in sub-Saharan Africa. In prior years we activated partnerships with JOHNSON'S, LISTERINE, and STAYFREE.		✓ On track
	Drive policy thought leadership and strategic engagements to expand healthcare access and coverage in at least three emerging markets (including Brazil, China and India), and lead three to five pilots to demonstrate the results of these efforts.	<ul style="list-style-type: none"> <li>More than 800 engagements conducted with government officials and other partners in Brazil, China, Malaysia, Mexico, Russia and Rwanda in 2019.</li> <li>Existing pilot projects to expand healthcare access and coverage in Brazil, China, Colombia, Indonesia, Mexico, Philippines, Russia and Rwanda are ongoing.</li> <li>Two new pilots launched: a private health insurance project in Malaysia to expand access to innovative medicines and premium surgical products; and a project in China to improve the case finding and diagnosis of TB, including drug-resistant TB.</li> </ul>		✓ On track
4. Fully integrate sustainable design solutions into our product innovation processes.	New and existing products representing 20% of Johnson & Johnson revenue achieve EARTHWARDS recognition for sustainable innovation improvements.	New and existing products representing 22% of Johnson & Johnson revenue achieved EARTHWARDS recognition.*		+ Exceeded

\* Based on availability of data, the percentage includes revenue from certain products recognized in the current reporting year. This is a change in methodology compared to prior years where the percentage excluded revenue from products recognized in the reporting year.

‡ Progress against our Health for Humanity 2020 Goals, and associated data have been assured by ERM CVS. See [independent assurance statements by ERM CVS](#).

GOAL	2020 TARGET	PROGRESS MADE IN 2016-2019‡	NOTABLE	STATUS
	Increase the recyclability of our Consumer Health product packaging to 90+% (on a weight basis) via design and partnerships in five key markets where mature recycling infrastructure exists (Canada, France, Germany, UK and U.S).* In three other markets where recycling infrastructure is less mature engage in partnerships to advance material recovery and recycling efforts.	<p>Continued partnerships with two co-ops in Brazil and one in India to advance material recovery and recycling efforts.</p> <p>Concluded the partnership in Vietnam focused on ocean plastics through Consumer Goods Forum and Trash Free Seas Alliance.</p>	<p>The main focus in 2019 was to advance our inclusive recycling model in Brazil by:</p> <ul style="list-style-type: none"> <li>collaborating with other companies through the Inclusive Waste Recycling Consortium (iWrc)</li> <li>identifying additional co-ops to expand the network of co-ops that have been socially fingerprinted**</li> <li>initiating development of a digital marketplace to help provide traceability of recycled materials recovered by socially fingerprinted** co-ops as they move through the system</li> </ul>	On track
5. Reduce our impacts on climate and water resources.	Reduce absolute carbon emissions 20% by 2020, and 80% by 2050.	CO <sub>2</sub> emissions decreased by 32% globally since 2010 (Scope 1 and Scope 2).		Achieved
	Produce/procure 35% of electricity from renewable sources by 2020; aspire to power all facilities with renewable energy by 2050.	30% of our electricity is produced or procured from renewable energy sources.		On track
	Conduct a comprehensive water risk assessment at 100% of manufacturing/R&D locations and implement resource protection plans at the high-risk sites.	<p>We completed the comprehensive water risk assessment at 100% of manufacturing/R&amp;D locations in 2019.</p> <p>By the end of 2019, 100% of all high-risk sites identified developed mitigation plans and budgeted for their implementation in 2020; 35% of these have already completed their mitigation plans.</p>	Newly acquired sites are assessed within three full calendar years post-acquisition.	On track

\* In 2018 **Johnson & Johnson Consumer Inc.** signed the New Plastics Economy Global Commitment. By joining this global multistakeholder initiative, we set a new ambitious 2025 plastics packaging commitment, which supersedes our 2020 target. Progress against the new 2025 commitment is being reported in this [section](#) of the Health for Humanity Report. We will continue reporting our progress on helping advance material recovery and recycling efforts in less mature markets in this Scorecard.

\*\* Social fingerprinting is a standardized process developed by Social Accountability International to measure and improve an organization's social performance. See more information [here](#).

‡ Progress against our Health for Humanity 2020 Goals, and associated data have been assured by ERM CVS. See [independent assurance statements by ERM CVS](#).

GOAL	2020 TARGET	PROGRESS MADE IN 2016-2019†	NOTABLE	STATUS
6. Collaborate with our suppliers to accelerate environmental and social improvements across the value chain.	Enroll suppliers covering 80% of our spend* in our Sustainable Procurement Program.	Enrolled suppliers covering approximately 71% of spend** in our Sustainable Procurement Program.		✓ On track
	Consistently achieve benchmark spending with U.S. diverse suppliers and small suppliers, and double the number of countries with established supplier diversity and inclusion programs.***	<ul style="list-style-type: none"> <li>Exceeded benchmark diverse supplier spending at 11% and benchmark small supplier spending at 18% of total U.S. spend.</li> <li>Expanded our supplier diversity and inclusion programs to three additional countries (France, Indonesia and Singapore) for a total of 16 countries against the baseline of six.</li> </ul>	The 16 countries outside the United States where we have started diverse supplier tracking are: Australia, Belgium, Brazil, Canada, China, Colombia, France, Germany, Indonesia, Japan, Mexico, Singapore, South Africa, Spain, Switzerland and UK.	✓ On track
7. Empower and engage the Johnson & Johnson family of employees to become the healthiest workforce.	Empower and engage employees toward a “personal best” in health and wellbeing via: training of at least 100,000 employees in the principles of ENERGY FOR PERFORMANCE;**** connecting at least 100,000 employees to their health via innovative digital health tools; and providing access to at least 100,000 employees to both fully implemented***** healthy eating and fully implemented healthy movement cultures.	<ul style="list-style-type: none"> <li>65,000 employees completed ENERGY FOR PERFORMANCE training.</li> <li>112,000 employees engaged in health and wellbeing via the use of digital health tools since 2016.</li> <li>120,000 and 113,000 employees provided access to 85% implemented healthy eating and healthy movement cultures, respectively.</li> </ul>	93,000 employees have completed the principles of ENERGY FOR PERFORMANCE training since the start of the program, representing 93% progress against our 2020 target of training 100,000 employees.**** We achieved our goal to connect at least 100,000 employees to their health via innovative digital health tools by 2020.	✓ On track

\* Based on spend data from prior calendar year.

\*\* Based on spend data from 2018.

\*\*\* Total spend represents addressable spend, i.e., products and services that procurement teams can negotiate with suppliers to meet business goals.

\*\*\*\* We count our 28,000 active employees who completed ENERGY FOR PERFORMANCE training prior to January 1, 2016, toward progress against this target.

\*\*\*\*\* Defined as 100% implementation of policies, programs and practices for both healthy eating and healthy movement.

† Progress against our Health for Humanity 2020 Goals, and associated data have been assured by ERM CVS. See [independent assurance statements by ERM CVS](#).